Company intelligence / Profile preview
CYTEA BIO
Montpellier, Languedoc-Roussillon, Francecytea.bio ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
Completed pre-IND consultation with FDA for CYT-102 with no red flags identified. Also completed EMA "scientific advice" consultation with similar outcome. Expects clinical studies to commence within 15-18 months of closing Series A investment round (as of October 2023).
- Therapeutic areas
- OncologyImmunology
- Modalities
- Antibody-effector cell constructsNK cell therapyMonoclonal antibody armed donor NK cells
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
EFS Besançon (PIBT)Bionoveo
Beyond the preview
Go deeper on CYTEA BIO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYTEA BIO.